ese drugs together may decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is a CYP3A4 substrate; pioglitazone is a weak inducer of CYP3A4.
Grapefruit juice: Taking velpatasvir with grapefruit juice may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); grapefruit is an inhibitor of P-gp. Grapefruit is also an inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Griseofulvin: Avoid coadministration of velpatasvir with griseofulvin. Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is a CYP3A4 substrate; griseofulvin is an inducer of CYP3A4.
H2-blockers: H2-blockers may be administered simultaneously with or 12 hours apart from velpatasvir. H2-blocker doses should not exceed doses comparable to famotidine 40 mg twice daily. Velpatasvir solubility decreases as pH increases; therefore, drugs that increase gastric pH are expected to decrease the concentrations of velpatasvir, potentially resulting in loss of antiviral efficacy.
Hydroxyprogesterone: Avoid coadministration of velpatasvir with hydroxyprogesterone. Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Hydroxyprogesterone is an in vitro inducer of CYP2B6; velpatasvir is a CYP2B6 substrate.
Idelalisib: Use caution when administering velpatasvir with idelalisib. Taking these drugs together may increase velpatasvir plasma concentrations, potentially resulting in adverse events. Idelalisib is a potent CYP3A4 inhibitor; velpatasvir is a substrate of CYP3A4.
Iloperidone: Use caution when administering velpatasvir with iloperidone. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); iloperidone is a weak inhibitor of P-gp.
Imatinib, STI-571: Use caution when administering velpatasvir with imatinib, STI-571. Taking these medications together may increase the plasma concentrations of velpatasvir and imatinib, potentially resulting in adverse events. Imatinib is a substrate for the drug transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). Velpatasvir is an inhibitor of P-gp and BCRP. Imatinib is also a CYP3A4 inhibitor; velpatasvir is a substrate of CYP3A4.
Indinavir: Use caution when administering velpatasvir with indinavir. Taking these medications together may increase the plasma concentrations of velpatasvir and indinavir, potentially resulting in adverse events. Indinavir is a substrate for the drug transporters P-glycoprotein (P-gp). Velpatasvir is an inhibitor of P-gp. Indinavir is also a potent CYP3A4 inhibitor; velpatasvir is a substrate of CYP3A4.
Isavuconazonium: Use caution when administering velpatasvir with isavuconazonium. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); isavuconazonium is a weak inhibitor of P-gp. Isavuconazonium is also an inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substra |
